WO2005039599A1 - ポリ乳酸混合物を含むマトリックスメタロプロテアーゼ抑制剤 - Google Patents
ポリ乳酸混合物を含むマトリックスメタロプロテアーゼ抑制剤 Download PDFInfo
- Publication number
- WO2005039599A1 WO2005039599A1 PCT/JP2004/015871 JP2004015871W WO2005039599A1 WO 2005039599 A1 WO2005039599 A1 WO 2005039599A1 JP 2004015871 W JP2004015871 W JP 2004015871W WO 2005039599 A1 WO2005039599 A1 WO 2005039599A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reaction
- polylactic acid
- mixture
- cyclic
- lactic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a matrix meta-oral protease inhibitor, and more particularly to a matrix meta-oral protease inhibitor comprising a mixture of cyclic and Z- or linear polylactic acid.
- the matrix meta-oral protease inhibitor of the present invention is useful for treating and / or preventing a disease associated with matrix metallo-oral protease overproduction. Background Art, ..
- Ma Bok 1 helix meth port protease (matrix metalloproteinases) (hereinafter sometimes abbreviated as MM P) is the extracellular matrix of the constituent proteins (e.g., joint lining, interstitial connective tissue, basement membrane or cartilage etc.
- MM P matrix metalloproteinases
- MMP-1, MMP-8 and MMP_13 collagenases (MMP-1, MMP-8 and MMP_13), gelatinases (MMP-2 and MMP-9), stromelysins (MMP3 and MMP-3) MMP-10), membrane-bound matrix meta-oral proteases (MMP-14, MMP-15, MMP-16 and ⁇ MMP-17), and others (MMP-7, MMP-11, MMP-12) It is divided into five groups.
- MMPs In normal tissues, the activity of MMPs is determined by (1) production of the latent enzyme (pro-MMP), (2) activation of the latent enzyme, and (3) Tissue Inhibitor of Metalloproteinases; It is controlled by the control of the activating enzyme by TIMPs), which balances the degradation of connective tissue by MMPs and the synthesis of new matrix tissue.
- pro-MMP latent enzyme
- TIMPs Tissue Inhibitor of Metalloproteinases
- TIMPs present in the living body become uncontrollable, and extracellular matritus is degraded, and arteriosclerosis and joint Inflammation (eg, rheumatoid arthritis and osteoarthritis), periodontal disease, ectopic vasculogenesis, neoplastic invasion, neoplastic metastasis, tissue ulceration (eg, corneal ulcer, gastric ulcer, epidermal ulcer)
- intractable diseases such as bone diseases (eg, osteoporosis, bone resorbable diseases such as loosening after artificial joint replacement), vascular reocclusion, vascular restenosis, HIV infection and diabetes complications It is one of the major causes.
- MMP inhibitors are considered to be useful as agents for preventing and treating these intractable diseases. Controlling the increase in MMP activity under pathological conditions with an MMP inhibitor is useful for the treatment of various diseases, and various MMP inhibitors have been reported.
- MMP inhibitor include marimastat having a hydroxamic acid skeleton (3R- (2,2-dimethyl-1S-methylcarbamoyl loop-opening pill force rubamoyl) -2S-hydroxy-5-methyl-hexano-1 Hydroxamic acid), flavonoids anthocyanidin, estaletin derivatives, sulfonyl amino acid derivatives, etc. are known, but from the viewpoints of activity, absorption in the body, toxicity, etc., the development of new MMPs inhibitors Is desired.
- An object of the present invention is to provide a novel inhibitor of matrix metalloproteinase by evaluating the inhibitory effect of cyclic and / or chain polylactic acid mixture on matrix metalloproteinase.
- Another object of the present invention is to provide a food or drink using the matrix meta-oral protease inhibitor.
- the present inventors have conducted intensive studies to solve the above problems, and as a result, lactic acid or Used lactide and evaluated the inhibition of matrix meta-oral protease using a polylactic acid mixture produced by polymerizing them.As a result, a cyclic, Z- or chain-like polylactic acid mixture having a condensation degree of 3 to 20 was obtained. Matrix meta-oral protease demonstrated its inhibitory effect.
- the present invention has been completed based on these findings.
- a matrix meta-oral protease inhibitor comprising a cyclic and Z- or chain-like polylactic acid mixture having a condensation degree of 3 to 20.
- the matrix meta-oral protease is Matrix Meta-oral protease-13 (MMP-3).
- the lactic acid, a repeating unit in the polylactic acid consists essentially of L-lactic acid.
- the matrix meta-oral protease inhibitor of the present invention can be used for treating or preventing a disease associated with overproduction of matrix metalloprotease.
- a food or drink comprising the above-described matrix meta-oral protease inhibitor of the present invention.
- a cyclic and Z- or linear polylactic acid mixture having a degree of condensation of 3 to 20 in the production of a matrix meta-mouth protease inhibitor.
- a matrix meta-oral protease comprising administering an effective amount of a cyclic and / or linear polylactic acid mixture having a degree of condensation of 3 to 20 to a mammal such as a human.
- a method is provided for suppressing.
- FIG. 1 shows a mass spectrum of the polylactic acid mixture obtained in Synthesis Example 1.
- FIG. 2 shows the MS spectrum of the reaction product obtained in Synthesis Example 2.
- FIG. 3 shows an overall NMR diagram of the reaction product obtained in Synthesis Example 2.
- FIG. 4 shows an enlarged view of a part of FIG.
- FIG. 5 shows an enlarged view of a part of FIG.
- FIG. 6 shows an overall view of the positive mode F ABMS spectrum of the product obtained in Synthesis Example 3. Range: m / z 10.0000 ⁇ : 1305/5900
- FIG. 7 shows an overall view of the negative mode F ABMS spectrum of the product obtained in Synthesis Example 3. Range: m / z 10.0000 to 20000000
- FIG. 8 is an enlarged view of the negative mode F ABMS spectrum of the product obtained in Synthesis Example 3. Range: m / z 10.0000-501.9260
- FIG. 9 shows an enlarged view of the negative mode FABMS spectrum of the product obtained in Synthesis Example 3. Range: m / z 490.2980 ⁇ : 1003 7700
- FIG. 10 shows an enlarged view of the negative mode F ABMS spectrum of the product obtained in Synthesis Example 3. Range: m / z 999.9500 ⁇ : 1504 3400
- FIG. 11 shows an enlarged view of the negative mode FABMS spectrum of the product obtained in Synthesis Example 3. Range: m / z 1484.5300-20000000
- FIG. 12 shows an overall view of the NMR spectrum of the product obtained in Synthesis Example 3.
- FIG. 13 is a view showing the effects of X01, ⁇ 02 and ⁇ 03 on ⁇ -3 expression of mouse B16 melanoma cells.
- ( ⁇ ) shows amplification of the ⁇ -3 fragment by PCR.
- the arrow (-) indicates the position of the ⁇ ⁇ -3 fragment (468 bases) amplified by PCR.
- ( ⁇ ) shows quantified data of the PCR product.
- the matrix meta-oral protease inhibitor of the present invention contains, as an active ingredient, a cyclic and / or chain polylactic acid mixture having a degree of condensation of 3 to 20, and is, for example, involved in the overproduction of matrix meta-oral protease.
- a cyclic and / or chain polylactic acid mixture having a degree of condensation of 3 to 20, and is, for example, involved in the overproduction of matrix meta-oral protease.
- a cyclic and / or chain polylactic acid mixture having a degree of condensation of 3 to 20
- For treatment or prevention of disease Can be used. '
- matrix meta-oral protease as used herein includes all cases where the activity of matrix meta-oral protease is suppressed in a living body, and preferably, the expression of matrix meta-oral protease is suppressed. means.
- diseases associated with overproduction of matrix meta-oral protease include both diseases caused by overproduction of matrix meta-oral protease and diseases associated with overproduction of matrix meta-oral protease.
- diseases associated with overproduction of matrix metalloprotease include arthritis diseases (eg, rheumatoid arthritis, osteoarthritis, osteoarthritis), bone resorption diseases (eg, osteoporosis), and diabetes Increased collagen breakdown, arteriosclerosis, aneurysm, cirrhosis, pulmonary fibrosis, periodontal disease, tissue ulceration (eg, corneal ulcer, gastric ulcer, epidermal ulcer), tumor invasion / metastasis, ectopic Angiogenesis, skin aging, vascular restenosis, vascular restenosis, HIV infection, diabetic complications and the like.
- arthritis diseases eg, rheumatoid arthritis, osteoarthritis, osteoarthritis
- bone resorption diseases eg, osteoporosis
- diabetes Increased collagen breakdown, arteriosclerosis, aneurysm, cirrhosis, pulmonary fibrosis, periodontal disease, tissue ulceration (eg, corneal ulcer, gastric ulcer, epidermal ulcer), tumor invasion
- a cyclic and / or chain polylactic acid mixture having a condensation degree of 3 to 20 is used as an active ingredient.
- polylactic acid mixture refers to a mixture in which cyclic and / or linear polylactic acid having a condensation degree of 3 to 20 is present at an arbitrary ratio. That is, the term “mixture” means a mixture of polylactic acids having any of the degrees of condensation of 3 to 20 and is also used as a concept including a mixture of cyclic and chain-like polylactic acids. . Such a “polylactic acid mixture” can be obtained by dehydrating and condensing acetic acid and purifying it by an appropriate method, as described below in this specification. In this specification, the term “polylactic acid mixture” is used for convenience, but includes a single component such as cyclic polylactic acid having a certain degree of condensation or chain polylactic acid having a certain degree of condensation. Also included are polylactic acids consisting of
- the degree of condensation means the number of lactic acid units which are repeating units in polylactic acid.
- the lactic acid includes all of L-lactic acid, D-lactic acid or a mixture of these in any proportion.
- the lactic acid consists essentially of L-lactic acid.
- the term "substantially” used herein means the ratio of L-lactic acid units in the polylactic acid mixture [that is, (L-lactic acid units ZL-lactic acid units + D-lactic acid units) X 100] It means 70% or more, preferably 80% or more, more preferably 85% or more, further preferably 90% or more, particularly preferably 95% or more. Note that the ratio of L-lactic acid units in the polylactic acid mixture depends on the ratio of L-lactic acid and D-lactic acid present in lactic acid used as a starting material.
- the method for producing a cyclic and / or chain-like polylactic acid mixture having a condensation degree of 3 to 20 is not particularly limited.
- Japanese Patent Application Laid-Open Nos. Japanese Patent Application No. 0-1303053 or Japanese Patent Application No. 11-39894 (the contents of these patent specifications are all incorporated by reference into the disclosure of the present specification). Can be obtained by the production method described in (1).
- a cyclic and / or chain polylactic acid mixture having a condensation degree of 3 to 20 can be obtained by the following method A.
- lactic acid preferably, lactic acid substantially composed of L-lactic acid
- inert atmosphere examples include nitrogen gas and argon gas, and it is preferable to use nitrogen gas.
- the dehydration / condensation reaction is carried out at a temperature of 110 to 210 ° C, preferably 130 to 190 ° C, under a reduced pressure of normal pressure to about ImmHg. It is particularly preferred to do so.
- the reaction time can be set as appropriate, and for example, the reaction can be performed for 1 to 20 hours. When stepwise decompression and stepwise heating are used, the reaction time is divided into two or more partial reaction times, and the reaction is performed by setting the pressure and temperature in each part.
- the pressure can be reduced, for example, from normal pressure to 150 mmHg to 3 mmHg, and when stepwise heating is used, for example, the temperature is increased from 145 ° C to 155 ° C to 185 ° C. Can be warmed. In practice, they are combined, for example, at 145 ° C for 3 hours at normal pressure, at 145 for 3 hours at 150 mmHg, at 155 for 3 hours at 3 mmHg and at 185 at 3 mmHg. 1. The reaction can be performed for 5 hours.
- ethanol and methanol are added to the reaction mixture obtained by the dehydration-condensation reaction, and the mixture is filtered and the filtrate is dried to obtain ethanol and methanol soluble components.
- the term “ethanol- and methanol-soluble matter” as used herein means a fraction that is soluble in a mixture of ethanol and methanol.
- the order and method of adding ethanol and methanol to the reaction mixture are not limited and may be appropriately selected.For example, it is possible to first add ethanol to the reaction mixture for the dehydration condensation reaction, and then add methanol. it can.
- Method B As another method for producing a cyclic and / or chain-like polylactic acid mixture having a condensation degree of 3 to 20 used in the present invention, for example, the method described in Japanese Patent Application No. 11-265711 is disclosed in Japanese Patent Application No. 11-265715. (Method B) or the method described in Japanese Patent Application No. 11-265572 (Method C) can be used (described in these patent specifications). Are all incorporated herein by reference.) Hereinafter, Method B and Method C will be specifically described.
- a lactic acid oligomer is obtained by polymerizing lactide in the presence of a lithium compound represented by RYL i (where R represents an aliphatic group or an aromatic group, and Y represents an oxygen atom or a zeo atom). It is a method of manufacturing.
- the use ratio of the lithium compound (RYLI) is 1 to 0.1 mol, preferably 0.2 to 0.3 mol, per 1 mol of lactide.
- the reaction temperature is from ⁇ 100 ° C. to 0 ° C., preferably from 178 ° C. to 150 ° C.
- the reaction is preferably started at a temperature between 178 ° C. and ⁇ 50 ° C. and gradually raised to room temperature.
- the reaction is preferably performed in the presence of a reaction solvent.
- a reaction solvent in addition to cyclic ethers such as tetrahydrofuran, etc., ethyl ether, dimethoxyethane and the like can be used.
- a reaction atmosphere an atmosphere of an inert gas such as nitrogen gas or argon is used.
- the reaction pressure is not particularly limited, and is preferably normal pressure.
- composition of the lactic acid oligomer obtained as described above (that is, the mixing ratio of the cyclic lactic acid oligomer and the chain lactic acid oligomer) varies depending on the lithium compound used as a reaction aid.
- Method C This method comprises the steps of (i) heating lactic acid to a temperature in the range of 120 to 140 ° C under a pressure of 350 to 400 mmH to cause a dehydration-condensation reaction and not to distill lactide. A first heating step to distill and remove only by-product water
- the linear lactic acid oligomer is cyclized by heating at 150 to 160 ° C. under a pressure condition of 0.1 to 3 mmHg to form a cyclic oligomer.
- Third heating step After completion of the second heating step, the linear lactic acid oligomer is cyclized by heating at 150 to 160 ° C. under a pressure condition of 0.1 to 3 mmHg to form a cyclic oligomer.
- lactic acid is heated under reduced pressure to cause a dehydrocondensation reaction.
- the reaction time in this case is 3 to 12 hours, preferably 5 to 6 hours.
- by-product water generated by dehydration-condensation of lactic acid is distilled off so that the reaction proceeds smoothly. Carry out so as not to evaporate.
- the reaction pressure is reduced, preferably kept at 300 to 500 mmHg, more preferably at 350 to 400 mmHg. Heat to 40 ° C, preferably in the range of 130 to 140 ° C.
- the reaction in the first heating step mainly produces a reaction product mainly composed of a dehydrated condensate of 3 to 23 molecules of lactic acid.
- the reaction pressure is lowered to a pressure of 10 to 50 mmHg, preferably 15 to 20 mmHg.
- this reaction is also carried out under the condition that by-product water is distilled off in order to make the reaction proceed smoothly, but lactide is not distilled off.
- the rate at which the reaction pressure is reduced to a pressure within the above range is 0.25 to 5 mmHgZ, preferably 0.5 to 5 in order to avoid lactide distillation and to increase the reaction efficiency. It is usually necessary to keep it in the range of lmmHg Z minutes. If the pressure reduction rate is lower than the above range, the time required to reduce the pressure to the predetermined pressure becomes longer, which is not preferable.On the other hand, if the pressure reduction rate is higher than the above range, the lactide is distilled off along with the by-product water. Is not preferred.
- the heating time in this case is 3 to 12 hours, preferably 5 to 6 hours.
- a lactic acid oligomer having an average degree of polymerization of 3 to 30, preferably 3 to 23 is obtained.
- the ratio of the cyclic oligomer in the oligomer is usually 70 to 80. % By weight.
- the reaction pressure is maintained at 0.25 to 5 mmHg, preferably 0.5 to LmmHg, and the temperature at 145 to 180 ° C, preferably 150 to 160 To continue the reaction.
- the reaction time is 3 to 12 hours, preferably 5 to 6 hours.
- the by-product water generated in this case is also distilled off. In this case, it is preferable to avoid the distillation of lactide. However, since the reaction product contains almost no lactide, it is not necessary to reduce the rate of pressure reduction particularly.
- lactide is reacted in the presence of an alkali metal compound represented by the formula (3): Me—N (R 1 ) (R 2 ).
- an alkali metal compound represented by the formula (3): Me—N (R 1 ) (R 2 ) will be described.
- Me represents an alkali metal.
- R 1 and R 2 each independently represent an aliphatic group or an aromatic group.
- Examples of the aliphatic group include linear or branched, cyclic, or saturated or unsaturated aliphatic hydrocarbon groups having 1 to 12 carbon atoms, preferably 1 to 6 carbon atoms, and combinations thereof. Specifically, alkyl groups such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, octyl, dodecyl, cyclopropyl, cyclopentyl, cyclooctyl, cyclooctyl And a cycloalkyl group such as dodecyl.
- the aliphatic group may be an unsaturated hydrocarbon group having a double bond or a triple bond.
- examples of the aromatic group include an aryl group and an arylalkyl group having 6 to 30 carbon atoms, preferably 6 to 20 carbon atoms, more preferably 6 to 12 carbon atoms, and still more preferably 6 to 10 carbon atoms.
- examples of the aryl group include phenyl, tolyl, and naphthyl
- examples of the arylalkyl group include benzyl, phenethyl, and naphthylmethyl.
- the aliphatic group and the aromatic group may have one or more substituents.
- the type of the substituent is not particularly limited, for example, a linear or branched, chain or cyclic alkyl group, a linear or branched, chain or cyclic alkenyl group, a linear or branched, chain or cyclic alkynyl group , Aryl group, acyloxy group, alkoxycarbonyl group, aryloxycarponyloxy group, carbamoyloxy group, carboxamide group, sulfonamide group, carbamoyl group, sulfamoyl group, alkoxy group, aryloxy group , Aryloxycarbonyl, alkoxycarbonyl, N-hole, arylsulfonyl, alkoxycarbonylamino, aryloxycarbonylamino, amino, ammonio, cyano, nitro, carboxyl Group, hydroxyl group, sulfo group, mercapto group
- Me represents an alkali metal.
- the alkali metal include Li, Na and K, and preferably Li.
- the compound represented by the formula (3) having an asymmetric carbon may be any of the (R) form, the (S) form, the (R) and the (S) form.
- the method for obtaining the alkali metal compound represented by the formula (3) is not particularly limited, and those skilled in the art can appropriately obtain it. It can be obtained by reacting a dialkylamine such as diisopropylamine with an alkylated alkali metal such as n-butyllithium. More specifically, this reaction is performed, for example, under a condition inert to the reaction such as under a nitrogen atmosphere, in a solution containing a dialkylamine in an inert solvent such as THF, and in an inert solvent such as hexane. And a solution containing an alkylated alkali metal, followed by stirring.
- the reaction temperature is not particularly limited as long as the reaction proceeds, but is preferably from 1 78 ° C to room temperature.
- the reaction time can be appropriately set.
- the amount of the compound of the formula (3) (M e -N (R 1 ) (R 2 )) is preferably 1 to 0 per mol of lactide. 1 mole, more preferably 0.2 to 0.3 mole.
- the reaction temperature at the time of conducting the polymerization reaction of lactide is not particularly limited as long as the reaction proceeds, but is preferably from 1100 ° C. to room temperature, more preferably from ⁇ 78 to room temperature.
- the polymerization reaction of lactide is preferably carried out in the presence of a reaction solvent.
- the reaction solvent is not particularly limited as long as it is a solvent inert to the reaction.
- a cyclic ether such as tetrahydrofuran, getyl ether, dimethoxyethane or the like can be used.
- As the reaction atmosphere use an inert gas atmosphere such as nitrogen gas or argon gas. Can be used.
- the reaction pressure is not particularly limited, and is preferably normal pressure.
- composition of the linear and cyclic lactic acid oligomer mixture obtained by the above method varies depending on the type of the compound of the formula (3) used as the reaction aid, the reaction conditions, and the like, but is preferably a chain rather than a cyclic lactic acid oligomer. High lactic acid oligomer content.
- the matrix metalloprotease inhibitor of the present invention may further contain, in addition to the above-mentioned essential components, as necessary, components used in pharmaceuticals, quasi-drugs, and the like within a range not impairing the effects of the present invention. Additives can be arbitrarily selected and used in combination.
- the matrix meta-oral protease inhibitor of the present invention can be used not only as a single pharmaceutical product but also as a compound in pharmaceutical products, quasi-drugs and the like.
- the form of the matrix meta-oral protease inhibitor of the present invention is not particularly limited, and an appropriate form most suitable for the purpose can be selected from preparation forms for oral administration or parenteral administration.
- Formulations suitable for oral administration include, for example, tablets, capsules, powders, drinks, granules, fine granules, syrups, solutions, emulsions, suspensions, and chewables.
- Pharmaceutical forms suitable for parenteral administration include, for example, injections (subcutaneous injection, intramuscular injection, or intravenous injection, etc.), external preparations, infusions, inhalants, sprays, etc. However, it is not limited to these.
- Liquid preparations suitable for oral administration include water, sucrose, sorbitol, fructose and other sugars, polyethylene glycol, propylene glycol and other daricols, sesame oil, olive oil, and Oils such as bean oil, p
- hydroxybenzoic acid esters can be manufactured using preservatives such as hydroxybenzoic acid esters, flavors such as strawberry flavor, and peppermint.
- preservatives such as hydroxybenzoic acid esters, flavors such as strawberry flavor, and peppermint.
- solid preparations such as capsules, tablets, powders, and granules
- excipients such as lactose, glucose, sucrose, mannitol, starch, disintegrants such as sodium alginate, and stearinic acid Lubricants such as magnesium and talc
- binders such as polyvinyl alcohol, hydroxypropyl cellulose, gelatin, surfactants such as fatty acid esters, and plasticizers such as glycerin can be used.
- Formulations for injection or infusion suitable for parenteral administration preferably contain the active substance in a sterile aqueous medium which is isotonic with the blood of the recipient, in dissolved or suspended form.
- a solution can be prepared using a salt solution, a glucose solution, or an aqueous medium composed of a mixture of saline and a glucose solution.
- Formulations for enteral administration can be prepared using carriers such as cocoa butter, hydrogenated fats, or hydrogenated carboxylic acids, and are provided as suppositories.
- the above-mentioned substance as an active ingredient can be dispersed as fine particles, so that it does not irritate the recipient's oral and airway mucous membranes and that the active ingredient is easily absorbed.
- a carrier for tightening can be used.
- Specific examples of the carrier include lactose and glycerin.
- Preparations in the form of aerosol or dry powder can be prepared depending on the substance as the active ingredient and the properties of the carrier used. These preparations for parenteral administration include one selected from glycols, oils, flavors, preservatives, excipients, disintegrants, lubricants, binders, surfactants, plasticizers, etc. Alternatively, two or more foods can be added.
- the dose and the number of administrations of the matrix meta-oral protease inhibitor of the present invention can be appropriately set depending on various factors including the purpose of administration, administration form, conditions such as the age, weight, or sex of the ingestor.
- the dose of the active ingredient is 1 to 10,000 mg / kg, preferably 10 to 2000 mg / kg, more preferably 10 to 200 mg / kg per day. It is preferable to administer the above dose of the preparation in 1 to 4 divided doses per day.
- the present invention further relates to a food or drink for inhibiting matrix meta-oral proteases, which contains a cyclic and / or linear polylactic acid mixture having a degree of condensation of 3 to 20. That is, the cyclic or linear polylactic acid mixture having a degree of condensation of 3 to 20 used in the present invention is used not only in the form of a single preparation as described above, but also used in a food or drink. be able to.
- the food and drink of the present invention are not particularly limited as long as they can be blended without decomposing the polylactic acid mixture.
- Specific examples of the food and drink products of the present invention include soft drinks, drinks, health foods, specified health foods, functional foods, functionally active foods, dietary supplements, supplements, feeds, feed additives, and the like.
- foods and drinks include, for example, sweets such as chewing gum, chocolate, candy, tablet confectionery, jelly, cookies, biscuits, yogurt, ice cream, frozen desserts such as ice confections, tea, soft drinks (juice, coffee) Cocoa, etc.), drinks such as nutritional drinks, beauty drinks, etc., and any foods and drinks such as bread, ham, soup, jam, spaghetti, frozen foods and the like.
- the polylactic acid mixture used in the present invention can be used by adding it to a seasoning or a food additive. By ingesting the food or drink of the present invention, a matrix meta-oral protease inhibitory effect is exhibited, and a safe food or drink that does not substantially exhibit harmful side effects can be provided.
- the food and drink of the present invention is obtained by directly mixing a polylactic acid mixture with general raw materials used for food. In this case, it can be obtained by dispersing and processing into a desired form by a known method.
- the foods and drinks of the present invention include all forms of foods and drinks, and the types thereof are not particularly limited.
- the composition of such foods and beverages should include proteins, lipids, carbohydrates, vitamins, and Z or minerals in addition to the cyclic and Z- or chain-like polylactic acid mixtures having a condensation degree of 3 to 20.
- the form of the food and drink is not particularly limited, and may be any of solid, powder, liquid, gel, slurry, etc. as long as it is easy to ingest.
- the content of the polylactic acid mixture in the food or drink is not particularly limited, but is generally 0.1 to 20% by weight, more preferably 0.1 to 10% by weight. / 0 or so.
- the amount of the polylactic acid mixture contained in the food or drink is preferably contained to such an extent that the objective of the present invention is to exert the inhibitory effect on the matrix-meta-protease. It is from about 1 ⁇ to about 108 , more preferably from about 0.5 to about 3 g.
- Synthesis Example 1 Production of polylactic acid mixture (hereinafter also referred to as XO1)
- the obtained polylactic acid was kept at 100 ° C., and after adding 1 O Oml of ethanol and 40 Om 1 of methanol, the mixture was allowed to cool. This was added to 50 Oml of methanol, stirred well, allowed to stand, and then filtered and purified. The filtrate was dried under reduced pressure and dissolved in acetate nitrile to make a total volume of 200 ml (stock solution).
- reaction temperature was increased to 150 to 160 ° C, and the reaction pressure was gradually reduced from 40 OmmHg over about 6 hours to 15 to 20 mmHg (pressure reduction rate: lmmHg / min).
- pressure reduction rate pressure reduction rate: lmmHg / min.
- FIG. 2 shows the MS spectrum of the reaction product obtained in Synthesis Example 2. Also, the synthesis example FIG. 3 shows an overall view of NMR of the reaction product obtained in 2, and FIGS. 4 and 5 show enlarged views of a part of FIG. Synthesis Example 3: Production of lactic acid oligomer mixture (hereinafter also referred to as X03)
- n-butyllithium (1.6 M hexane solution) 0.63 mL (lmmo 1) was added to a solution of 0.101 g (lmmol) of diisopropylamine in 5 mL of THF and stirred for 10 minutes. Then, after adding lithium diisopropylamide (LDA), 0.577 g (4 mmol) of L- (1-)-lactide in 4 mL of THF was added, and the mixture was stirred and reacted for 15 minutes. To this reaction mixture, 20 mL of a saturated aqueous solution of ammonium chloride was added to process the reaction, and 1 OmL of water was further added.
- LDA lithium diisopropylamide
- the mixture was extracted five times with THF (5 OmL), and the organic layer was dried over anhydrous sodium sulfate. After the anhydrous sodium sulfate was filtered off, the organic solvent was concentrated under reduced pressure to obtain 0.53 g of a crude product. 6 mL of ether was added to the obtained crude product, which was immersed in an ultrasonic cleaner for 10 minutes, and filtered to obtain 0.39 g of a white solid product having a melting point of 125 to 129 ° C.
- the physical property data of the obtained product is shown in FIGS.
- the FABMS and NMR data shown in Figures 6 to 12 indicate that the solid product contains a trimer to 21-mer cyclic lactic acid oligomer and a trimer to 27-mer chain lactic acid oligomer.
- Mouse B16 melanoma cell line (RCB 0557) was obtained from RIKEN Cell Bank (Tsukuba).
- B 16 melanoma cells (1 x 10 5 initial meniscus) were treated with fetal bovine serum (10%), L-glutamine (0.3 mg / ml), penicillin (lOOunit / ml)
- the cells were cultured at 37 ° C for 48 hours using 20 ml of a DMEM culture solution containing streptomycin and 0.1 mg / ml.
- the cells were further cultured at 37 ° C. for 48 hours in the above culture solution containing lactoalbumin hydrolysate instead of fetal bovine serum.
- RNA was prepared from the mouse B16 melanoma cells obtained by the above (1) using IS0GEN (RNA extraction reagent, Futaba Gene). That is, 1 ml of IS0GEN was added to B16 melanoma cells collected from a plate having a diameter of 10 cm, and the cells were lysed by aspirating with a pipet. After leaving the mixture at room temperature for 5 minutes, 0.2 ml of a mouthpiece was added, and the mixture was shaken vigorously for 15 seconds, and then left at room temperature for 3 minutes. The aqueous phase was collected by centrifugation at 12, OOOrpm for 15 minutes at 4 ° C.
- IS0GEN RNA extraction reagent, Futaba Gene
- RA / primer mixture was prepared with the following composition.
- the mixture was heated at 70 ° C. for 10 minutes. Place on ice for 1 minute and add the following reagents in order.
- nucleotide sequence of mouse MMP-3 (Accession No. III-010809) already published in public databases, the following nucleotides were synthesized as primers to specifically amplify only the gene by PCR. That is, 5′-TGGGACTCTACCACTCAGCCAAGG-3, (24-mer) (SEQ ID NO: 1) is used as the sense primer, and 5′-CCAGGGTGTGAATGCTTTTAGG- is used as the 3 ′ antisense primer. 3 ′ (22-mer) (SEQ ID NO: 2) was synthesized. The synthesized oligonucleotides were chemically synthesized using a fully automatic DNA synthesizer (Applied Biosystems).
- PCR was performed using the cDNA prepared in (3) above as the type III and the primers prepared in (4) above.
- the composition of the PCR reaction solution is as follows.
- PCR reaction was performed. PCR was first heated at 94 ° C for 3 minutes, followed by heat denaturation at 94 ° C for 30 seconds, annealing at 55 ° C for 30 seconds, and 72 ° C for 30 seconds. The conditions for the elongation reaction were 1 cycle, and 30 cycles were performed. After the reaction was completed, the PCR product was subjected to 1.5% agarose gel electrophoresis. PCR products were detected by UV irradiation after immersing the electrophoresis gel in a buffer containing ethidium promide for 30 minutes. The amplified product was DNA consisting of about 470 nucleotides. In mouse B16 melanoma cell culture, the amount of PCR product was significantly reduced by adding X01, X02, and X03 to the culture at a concentration of 500 ⁇ g / ml. ( Figure 13).
- the PCR product amplified in (5) above was excised and purified from agarose gel using Gene Clean Kit (Q-BIO gene).
- the PCR product was ligated into a T-Vector, and the recombinant plasmid was transformed into Escherichia coli (JM109).
- JM109 Escherichia coli
- a single colony is cultured in a Terrific Broth medium, the plasmid is purified, and an automated fluorescent DNA sequencer (Applied Biosystems, 373) is purified using ABI PRISM Big-Dye Terminator Cycle Sequence Kit Version 1.1 (Applied Biosystems). (Type). This confirmed that the PCR product was a fragment of the mouse MMP-3 gene (468 bases, corresponding to SEQ ID NO: 753-1220 in Accession No. M_010809).
- the polylactic acid mixture used as an active ingredient in the present invention is a low condensate of lactic acid derived from a biological component, and therefore has high biocompatibility and has few side effects.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-363284 | 2003-10-23 | ||
JP2003363284A JP2005126361A (ja) | 2003-10-23 | 2003-10-23 | ポリ乳酸混合物を含むマトリックスメタロプロテアーゼ抑制剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005039599A1 true WO2005039599A1 (ja) | 2005-05-06 |
Family
ID=34510036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/015871 WO2005039599A1 (ja) | 2003-10-23 | 2004-10-20 | ポリ乳酸混合物を含むマトリックスメタロプロテアーゼ抑制剤 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2005126361A (ja) |
TW (1) | TW200524621A (ja) |
WO (1) | WO2005039599A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4800870B2 (ja) * | 2006-07-28 | 2011-10-26 | 北海道三井化学株式会社 | マトリックスメタロプロテアーゼ阻害剤 |
KR101518014B1 (ko) | 2007-03-30 | 2015-05-06 | 라큐어 에이비 | 부인과 질환의 치료에서의 락트산 올리고머의 용도 |
JP5150669B2 (ja) * | 2010-03-15 | 2013-02-20 | 株式会社ユウコーエンタープライズ | 胃の中に安全に硫化水素ガスを発生させる方法並びに該方法に用いられる健康食品並びに医薬品 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09227388A (ja) * | 1996-02-15 | 1997-09-02 | Naganushi Tetsuaki | 大腸癌、食道癌及び乳癌より選ばれた癌に用いる抗悪性腫瘍剤 |
JPH10130153A (ja) * | 1996-10-28 | 1998-05-19 | Shiyumeidou:Kk | 大腸癌、食道癌及び乳癌より選ばれた癌に用いる 抗悪性腫瘍剤 |
-
2003
- 2003-10-23 JP JP2003363284A patent/JP2005126361A/ja active Pending
-
2004
- 2004-10-20 WO PCT/JP2004/015871 patent/WO2005039599A1/ja active Application Filing
- 2004-10-22 TW TW093132260A patent/TW200524621A/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09227388A (ja) * | 1996-02-15 | 1997-09-02 | Naganushi Tetsuaki | 大腸癌、食道癌及び乳癌より選ばれた癌に用いる抗悪性腫瘍剤 |
JPH10130153A (ja) * | 1996-10-28 | 1998-05-19 | Shiyumeidou:Kk | 大腸癌、食道癌及び乳癌より選ばれた癌に用いる 抗悪性腫瘍剤 |
Non-Patent Citations (3)
Title |
---|
SHIMA I. ET AL.: "Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behaviour of Esophageal carcinoma", CANCER, vol. 70, no. 12, 1992, pages 2747 - 2753, XP002983485 * |
TANAKA H. ET AL.: "Antitumor efficacy of hypothemycin, a new ras-signaling inhibitor", JPN. J. CANCER RES., vol. 90, 1999, pages 1139 - 1145, XP002983484 * |
THOMASSET N. ET AL.: "Expression of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development", AMERICAN JOURNAL OF PATHOLOGY, vol. 153, no. 2, 1998, pages 457 - 467, XP002983486 * |
Also Published As
Publication number | Publication date |
---|---|
TW200524621A (en) | 2005-08-01 |
JP2005126361A (ja) | 2005-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1403302A1 (en) | Process for producing lactic acid oligomer | |
JP6189994B2 (ja) | ジペプチジルペプチダーゼ−iv阻害用飲食品組成物 | |
JP5141553B2 (ja) | 抗炎症用組成物 | |
WO2001021182A1 (fr) | Agents ameliorant la resistance physique et agents favorisant l'accumulation de glycogene | |
WO2005039599A1 (ja) | ポリ乳酸混合物を含むマトリックスメタロプロテアーゼ抑制剤 | |
US20030083368A1 (en) | Cancer cell implantation inhibitors | |
US6825314B1 (en) | Process for the preparation of cyclic lactic acid oligomers | |
JP2000344672A (ja) | マトリックスメタロプロテアーゼ阻害剤 | |
CN112352046A (zh) | 麦角硫因、抗坏血酸2-葡糖苷、抗坏血酸和它们的组合的成肌分化促进作用 | |
KR101138714B1 (ko) | 효모 가수분해물을 유효성분으로 포함하는 연골세포 손상방지 및 재생효과를 갖는 조성물 | |
WO2003039560A1 (fr) | Agent antitumoral contenant un melange d'oligomeres d'acide lactique | |
KR20200000957A (ko) | 프로피오니바크테리움 후레우덴레이키, 이의 배양액 또는 이의 사균체를 유효성분으로 함유하는 골질환의 예방 또는 치료용 조성물 | |
JP5439671B2 (ja) | 抗がん剤 | |
EP1219297A1 (en) | Antiobestic agents | |
JP2008214232A (ja) | コラーゲン合成促進剤 | |
JPWO2003007937A1 (ja) | 環状ポリ乳酸を含む抗腫瘍剤 | |
JP5930507B2 (ja) | ヒアルロン酸産生促進剤 | |
JP2004123620A (ja) | 4−ヒドロキシ−1−ベンゾピラン−2−オン化合物及びその利用 | |
WO2003105869A1 (ja) | 抗癌剤副作用抑制剤 | |
JP2005206520A (ja) | アテローム性動脈硬化抑制剤ならびにこれを含む食品および医薬 | |
JPWO2003105870A1 (ja) | ベロ毒素産生抑制剤 | |
KR101735584B1 (ko) | 신규한 ((페닐 테트라졸릴)메틸)옥사디아졸 유도체 및 이의 용도 | |
JP2016040315A (ja) | ヒアルロン酸産生促進剤 | |
KR20180119958A (ko) | 히스톤 탈아세틸화효소 7의 억제제를 유효성분으로 포함하는 페이로니병의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |